Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naive patients with Gaucher disease

dc.creatorZimran, A.
dc.creatorDurán Saavedra, Gloria Patricia
dc.creatorGiraldo, P.
dc.creatorRosenbaum, H.
dc.creatorGiona, F.
dc.creatorPetakov, M.
dc.creatorMunoz, E.T.
dc.creatorSolorio-Meza, S.E.
dc.creatorCooper, P.A.
dc.creatorVarughese, S.
dc.creatorAlon, S.
dc.creatorChertkoff, R.
dc.date.accessioned2020-10-28T14:12:12Z
dc.date.available2020-10-28T14:12:12Z
dc.date.created2020-10-28T14:12:12Z
dc.date.issued2019
dc.identifier10.1016/j.bcmd.2016.07.002
dc.identifier1079-9796
dc.identifier1096-0961
dc.identifierhttps://doi.org/10.1016/j.bcmd.2016.07.002
dc.identifierhttps://repositorio.uc.cl/handle/11534/48162
dc.languageen
dc.rightsacceso abierto
dc.subjectGaucher disease
dc.subjectEnzyme replacement therapy
dc.subjectTaliglucerase alfa
dc.subjectSplenomegaly
dc.subjectHepatomegaly
dc.subjectAnemia
dc.subjectThrombocytopenia
dc.subjectChitotriosidase
dc.subjectChemokine (CC motif) ligand 18
dc.titleLong-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naive patients with Gaucher disease
dc.typeartículo


Este ítem pertenece a la siguiente institución